PatientsVille.com Logo

ASTHENIA and Augmentin

PatientsVille

ASTHENIA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for ASTHENIA

ASTHENIA treatment research studies

Augmentin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Augmentin Side Effects

Diarrhoea (341)
Pruritus (324)
Rash (236)
Pyrexia (227)
Jaundice (205)
Erythema (198)
Alanine Aminotransferase Increased (194)
Dyspnoea (186)
Urticaria (180)
Anaphylactic Shock (179)
Vomiting (173)
Aspartate Aminotransferase Increased (168)
Blood Alkaline Phosphatase Increased (164)
Nausea (152)
Abdominal Pain (145)
Hypotension (136)
Cholestasis (136)
Hepatitis Cholestatic (134)
Gamma-glutamyltransferase Increased (130)
Malaise (119)
Hypersensitivity (113)
Blood Bilirubin Increased (108)
Rash Maculo-papular (104)
Face Oedema (103)
Asthenia (98)
Hepatitis (96)
Toxic Skin Eruption (92)
Abdominal Pain Upper (89)
Anaphylactic Reaction (86)
Renal Failure Acute (79)
Chromaturia (78)
Oedema Peripheral (74)
Eosinophilia (74)
Purpura (73)
Angioedema (73)
Dizziness (71)
Anaemia (69)
Bronchospasm (69)
International Normalised Ratio Increased (69)
Thrombocytopenia (67)
Tachycardia (66)
Rash Erythematous (65)
Inflammation (63)
Oedema (63)
Fatigue (61)
Pain (54)
Dehydration (54)
Anorexia (53)
Death (53)
Blood Pressure Decreased (53)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

3rd day on augmentin and i'm getting chest pain didn't think it could be related and really bad nausea when I took it this morning. They don't list that as a side effect.

And it has blister now ,,,im afraid i dont know what to do,,,

Augmentin 625 ; ive been on it for 2 days,feeling sick and central chest pain [ like bad heartburn]

Augmentin 625: 2x a day I've been on it for 2 days. Experienced unexplained joint pains and swelling of my hands, feet & face. Can see flashes on my left eye on the 2nd day. Have also noticed that I always want to eat.

Buna imi poate spune si mie cineva ce contine augumentinu ca eu sunt alergica la amoxicilina

Can augmentine 625 mg twice daily for five days cause as a side effect Hyperthermia

Doctor had me take amoxicillin 500mg because of sinus infection. I toke 4x500mg for 10days. It cleared up the infection but I have had acute gout attacks for over a month. my feet/hands/wrists/knees have developed terrible pain to the point that I co

Due to elevated liver enzyme levels and an elevated ANA, my previous doctor gave me a diagnosis of autoimmune hepatitis. After reviewing my charts, my current doctor believes that it was an autoimmune response to 3 back-to-back courses of amoxicillin

Has anyone developed boday aches anda fever following only a second dose? I was perfectly fine,no fever just abronchial inflamation. feel horrible!

I am on it for second day too. Only side effects I have had was diarrhea, slight headache, and for some reason I have a herpes blister on my hand, which is where the virus lies dormant (until now). I am hoping the blister will go away right after I g

ASTHENIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
Condition: Asthenia
Intervention: Drug: methylphenidate
Outcome Measures: Intensity of Asthenia assessed with the verbal numeric scale (VNS) included on the Edmonton Symptom Assessment System (ESAS);   Intensity of Asthenia assessed with the subscale for fatigue of the Functional Assessment of Cancer Therapy (FACT-F);   Intensity of Asthenia assessed with the verbal numeric scale (VNS) included on the Edmonton Symptom Assessment System (ESAS) and the subscale for fatigue of the Functional Assessment of Cancer Therapy (FACT-F).;   Intensity of other symptoms assessed with the Edmonton Symptom Assessment System (ESAS);   Number of participants with treatment-related adverse events and severity of these adverse events.;   Cognitive level.
2 Recruiting Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Conditions: Muscle Weakness;   Pulmonary Arterial Hypertension
Intervention:
Outcome Measures: Plasma growth and differentiation factor 15 levels in participants with and without muscle wasting;   Correlation of plasma Growth and differentiation factor 15 levels with muscle strength;   Change in fibre type in muscle biopsy;   GDF-15 levels in biopsy specimens;   Correlation of plasma Growth and differentiation factor 15 levels with brain natriuretic protein levels;   Correlation of plasma Growth and differentiation factor 15 levels with fat free mass index;   Correlation of plasma Growth and differentiation factor 15 levels with quality of life;   Correlation of plasma Growth and differentiation factor 15 levels with exercise tolerance;   Correlation of plasma Growth and differentiation factor levels 15 with physical activity levels;   Correlation of plasma Growth and differentiation factor levels 15 with echocardiographic measures of severity of pulmonary hypertension;   Correlation of GDF-15 levels in biopsy specimens with muscle wasting and weakness;   Determine the contribution of atrophy and autophagy to muscle wasting in PAH;   Determine the contribution of SMAD and non-SMAD signalling pathways to the development of muscle weakness and wasting in PAH
3 Unknown  Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Conditions: Intensive Care Unit;   Muscle Weakness
Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA);   Device: Sham
Outcome Measures: Lower extremity strength, at hospital discharge, of 3 bilateral muscle groups (pretibial, triceps surae, and quadriceps) measured via MMT using a composite Medical Research Council (MRC) score;   Individual muscle strength: Pretibial, triceps surae, and quadriceps (MRC score) between those who receive NMES vs. sham sessions;   Overall body strength: 6 bilateral muscle groups in arms and legs (MRC composite score) between those who receive NMES vs. sham sessions;   Overall body strength: Hand grip between those who receive NMES vs. sham sessions;   Respiratory muscle strength: Maximum Inspiratory Pressure (MIP) between those who receive NMES vs. sham sessions;   Functional status as measured by modified Functional Independence Measurement (FIM) score between those receiving NMES vs. sham sessions;   Duration of mechanical ventilation;   ICU and hospital length of stay;   ICU and in-hospital mortality;   Total hospital charges;   Hospital discharge destination (e.g., home, rehab facility);   Mean change in subject's lower extremity MRC composite score from baseline;   ICU Delirium;   Subgroup analysis
4 Recruiting Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.
Condition: Polyneuropathy
Intervention: Procedure: Muscular electrostimulation and percutaneus muscular biopsy.
Outcome Measures: muscular weakness;   time of weaning
5 Recruiting Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders
Conditions: Brain Disorders;   Birth Defects;   Craniofacial Differences
Intervention:
Outcome Measures: Characterize the phenotype of Moebius syndrome and other congenital facial weakness disorders to determine the prevalence of associated malformations and inform subsequent genetic studies.;   Obtain imaging studies to explore cranial nerve structure and associated brain/brainstem and white matter tract anomalies and associate with the neurocognitive and behavioral phenotype of the patients.
6 Recruiting Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Conditions: Respiratory Complication;   Morbid Obesity
Interventions: Device: Accelomyography;   Drug: Neostigmine;   Device: Qualitative Monitor
Outcome Measure: Respiratory Events (RE)
7 Unknown  A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome
Condition: Postpoliomyelitis Syndrome
Interventions: Drug: L-carnitine and piracetam;   Drug: Placebo
Outcome Measures: Changes in Muscle Weakness;   Changes in fatigue;   Changes in muscle pain;   Changes in daytime sleepiness;   Changes in quality of life;   Changes in daily function;   Changes in depressive mood;   Changes in oxidative capacity in skeletal muscle;   Occurrence of adverse events
8 Unknown  The Effects of the Inspiratory Muscle Plus Aerobic Training Compare to Aerobic Training Alone in Heart Failure Patients.
Condition: Heart Failure
Intervention: Other: Inspiratory muscle added by aerobic to aerobic alone
Outcome Measures: To compare effects of inspiratory muscle training added by aerobic training to aerobic training alone in heart failure patients with inspiratory muscle weakness.;   To compare effects between the training groups evaluating strength and endurance of inspiratory muscles; functional capacity; the physical and psychological perceptions of quality of life and heart rate variability and sleep apnea.
9 Unknown  Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Fosinopril;   Other: lactose
Outcome Measures: Changes in phosphorylation of components of the atrogene pathway;   Quadriceps endurance assessed non-volitionally;   Effect of ACE-I on quadriceps maximum voluntary contraction force;   Effect of ACE-I on quadriceps bulk (cross-sectional area);   Effect of ACE-I on systemic inflammation and serum IGF-1
10 Recruiting Vibrational-proprioceptive Resistance Exercise Training Versus Neuromuscular Electrical Stimulation Training in Elderly People With Muscle Weakness
Conditions: Muscle Weakness Condition;   Therapy Effect
Interventions: Device: Vibrational-proprioceptive Resistance Exercise Training;   Device: Neuromuscular Electrical Stimulation Training
Outcome Measure: Maximum voluntary knee extension torque
11 Recruiting EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With SCI
Condition: Spinal Cord Injuries or Similar Neurological Weakness.
Intervention: Device: Ekso exoskeleton
Outcome Measures: Change in 6 Minute Walk Test from baseline in distance, RPE and oxygen uptake;   change in 10 meter walk test from baseline in gait speed;   Ratio of number of steps/walking time;   2 Minute Walk Test;   Walk time to stand time ratio on a particular assistive device
12 Unknown  Muscle Atrophy in Sepsis
Conditions: Atrophy;   Sepsis;   Weakness
Intervention:
Outcome Measures: Electrical stimulation will be associated with upregulation of anabolic signaling molecules and genes, downregulation of catabolic signaling molecules and genes within skeletal muscle of patients with sepsis;   Electrical stimulation will be associated with improvement of histologic and electrophysiologic and strength parameters within skeletal muscle of patients with sepsis
13 Recruiting Memantine for Enhanced Stroke Recovery
Conditions: Ischemic Stroke;   Upper Extremity Weakness
Interventions: Drug: Memantine;   Drug: Placebo (for memantine)
Outcome Measures: Fugl-Meyer Assessment;   Adverse events;   Adverse Events;   Motor Activity Log (MAL);   Ten Meter Walk Test;   Stroke Impact Scale (SIS);   Cancellation Tests;   Cancellations Tests;   Grip Strength Test;   Montreal Cognitive Assessment (MoCA©)
14 Unknown  Vitamin D 2 to Dialysis Patients
Conditions: Kidney Disease;   Muscle Weakness;   Pain;   Fractures, Bone
Intervention: Drug: Ergocalciferol (Vitamin D 2)
Outcome Measures: We hypothesize that a large proportion of the study population will be 25-hydroxyvitamin D insufficient (< 25ng/ml), and performance on the muscle function tests will correlate with 25OHD levels.;   We expect a 25% improvement in mean TUG values at twelve weeks in the treatment group when compared to the placebo group.
15 Recruiting The Effect of Activity-based Training in Patients With Hand-related Injuries Grouped Using Sense of Coherence Scores
Condition: Hand Related Injuries
Interventions: Other: Joint mobility exercises hand therapy;   Other: activity-based hand therapy
Outcome Measures: Disabilities of the Arm, Shoulder, and Hand questionnaire;   The EQ-5D Quality of life questionnaire;   Sense of Coherence Questionnaire;   Canadian Occupational Performance Measure (COPM) Canadian Occupational Performance Measure (COPM);   Satisfaction with daily living and rehabilitation
16 Unknown  Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
Conditions: Cardiac Complications;   Signs and Symptoms;   Muscle Weakness;   Anemia;   Hypotension
Intervention: Drug: L-Carnitine Injection
Outcome Measures: weakness;   improvement of hypotension and hematology profile;   reduction of erythropoietin requirement;   increase of plasma carnitine concentration;   including all the components of the primary endpoints for their further assessment;   improvement of the nutritional indexes;   intradialytic complications (muscle symptoms, dyspnea, palpitations);   quality of life
17 Recruiting TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
Conditions: Intensive Care Unit Acquired Weakness;   Critical Care;   Mechanical Ventilation;   Respiratory Failure
Intervention: Device: In-bed leg cycle ergometry
Outcome Measures: Number of in-bed leg cycling research sessions terminated (composite outcome);   Number of adverse events: Intravascular catheter or tube dislodgement rate during in-bed cycling;   Daily research session delivery rate;   Rate of outcome measure ascertainment in assessable patients at ICU awakening;   Rate of outcome measure ascertainment in assessable patients at ICU discharge;   Rate of outcome measure ascertainment in assessable patients at hospital discharge;   Consent rate feasibility
18 Unknown  The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care
Conditions: Accidental Falls;   Muscle Weakness;   Gait;   Depression;   Behavior
Interventions: Behavioral: Interpersonal Interaction;   Behavioral: Walking Program
Outcome Measures: Falls;   Fitness;   Balance;   Grip Strength;   Gait speed;   Physical Activities of Daily Living;   Depression;   Behavioral problems;   Vital signs
19 Recruiting ICU Acquired Neuromyopathy and Diaphragm Function
Conditions: Critical Illness Myopathy;   Respiratory Paralysis
Intervention: Other: Non invasive phrenic nerve stimulation
Outcome Measures: Twitch tracheal pressure during airway occlusion (expressed in cmH2O);   extubation success (defined as no need reintubation during the 48h after extubation)
20 Recruiting Contralateral Strength-training After Anterior Cruciate Ligament (ACL) Reconstruction
Condition: Muscle Weakness After ACL Reconstruction
Interventions: Behavioral: Neuromuscular electrical stimulation;   Behavioral: eccentric training
Outcome Measures: Change in bilateral quadriceps muscle strength [Nm];   Change in quadriceps muscle activation;   Change in muscle architecture;   Change in self-reported questionnaire outcomes (KOOS, WOMAClk);   functional test outcomes